This review is focused on present and future biomarkers, along with pharmacogenomics used in clinical practice for kidney transplantation. It aims to highlight biomarkers that could potentially be used to improve kidney transplant early and long-term graft survival, but also potentially patient co-morbidity. Future directions for improving outcomes are discussed, which include immune tolerance and personalising immunosuppression regimens.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s40291-018-0349-5 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!